Bulletin 2009/07 - European Patent Office
13.12.2012 • Views
Share Embed Flag

Bulletin 2009/07 - European Patent Office

Bulletin 2009/07 - European Patent Office

Bulletin 2009/07 - European Patent Office

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
application.epo.org

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

(A61K) II.1(1)<br />

• LIPOSOMAL INFLUENZA VACCINE COM-<br />

POSITION AND METHOD<br />

• COMPOSITION LIPOSOMALE DE VACCIN<br />

CONTRE LA GRIPPE ET UTILISATION<br />

(73) YISSUM RESEARCH DEVELOPMENT COM-<br />

PANY OF THE HEBREW UNIVERSITY OF<br />

JERUSALEM, 46 Jabotinsky Street, 91042<br />

Jerusalem, IL<br />

(72) KEDAR, Eliezer, 96920 Jerusalem, IL<br />

BABAI, Ilan, 49612 Petach Tikva, IL<br />

BARENHOLZ, Yechezkel, 937<strong>07</strong> Jerusalem,<br />

IL<br />

(74) Vossius & Partner, Siebertstraße 4, 81675<br />

München, DE<br />

A61K 9/127 → (51) B01J 13/22<br />

(51) A61K 9/16 (11) 1 796 646 B1<br />

A61K 38/48 A61K 8/99<br />

A61P 17/00 A61K 38/16<br />

(25) En (26) En<br />

(21) 05791297.4 (22) 24.08.2005<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HU IE IS IT LI LT LU LV MC NL PL PT RO<br />

SE SI SK TR<br />

(43) 20.06.20<strong>07</strong><br />

(86) US 2005/030281 24.08.2005<br />

(87) WO 2006/039014 2006/15 13.04.2006<br />

(30) 01.10.2004 US 957004<br />

(54) • KOSMETISCHE NEUROTOXIN-ZUSAM-<br />

MENSETZUNGEN MIT EINER BOTULI-<br />

NUSTOXIN-KOMPONENTE UND<br />

VERFAHREN<br />

• COSMETIC NEUROTOXIN COMPOSITIONS<br />

COMPRISING A BOTULINUM TOXIN<br />

COMPONENT AND METHODS<br />

• COMPOSITIONS COSMETIQUES DE NEU-<br />

ROTOXINE COMPRENANT UN COMPO-<br />

SANT DE TOXINE BOTULINIQUE, ET<br />

PROCEDES CORRESPONDANTS<br />

(73) ALLERGAN, INC., 2525 Dupont Drive, Irvine<br />

CA 92612, US<br />

(72) FIRST, Eric, R., Boston, MA 02127-2305, US<br />

(74) HOFFMANN EITLE, <strong>Patent</strong>- und Rechtsanwälte<br />

Arabellastrasse 4, 81925 München, DE<br />

(51) A61K 9/20 (11) 1 937 221 B1<br />

A61K 31/551<br />

(25) De (26) De<br />

(21) 06805947.6 (22) 29.09.2006<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HU IE IS IT LI LT LU LV MC NL PL PT RO<br />

SE SI SK TR<br />

AL BA HR MK RS<br />

(43) 02.<strong>07</strong>.2008<br />

(86) EP 2006/009466 29.09.2006<br />

(87) WO 20<strong>07</strong>/042160 20<strong>07</strong>/16 19.04.20<strong>07</strong><br />

(30) 08.10.2005 DE 102005048293<br />

(54) • RETARDFORMULIERUNG FÜR PRALNA-<br />

CASAN<br />

• RETARD FORMULATION FOR PRALNACA-<br />

SAN<br />

• FORMULATION A EFFET RETARD POUR<br />

PRALNACASAN<br />

(73) Sanofi-Aventis Deutschland GmbH, Brüningstrasse<br />

50, 65929 Frankfurt am Main,<br />

DE<br />

(72) SOENNICHSEN, Caren, 65926 Frankfurt am<br />

Main, DE<br />

WESCH, Roland, 65926 Frankfurt am Main,<br />

DE<br />

MEIER, Heiko, 65926 Frankfurt am Main, DE<br />

(51) A61K 9/22 (11) 1 663 168 B1<br />

A61K 9/70 A61K 9/68<br />

(25) En (26) En<br />

(21) 04769203.3 (22) 27.08.2004<br />

Europäisches <strong>Patent</strong>blatt<br />

<strong>European</strong> <strong>Patent</strong> <strong>Bulletin</strong><br />

<strong>Bulletin</strong> européen des brevets<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HU IE IT LI LU MC NL PL PT RO SE SI SK<br />

TR<br />

(43) <strong>07</strong>.06.2006<br />

(86) IB 2004/002787 27.08.2004<br />

(87) WO 2005/023227 2005/11 17.03.2005<br />

(30) 08.09.2003 SE 0302387<br />

08.09.2003 US 501061 P<br />

(54) • NIKOTINFORMULIERUNGEN UND IHRE<br />

VERWENDUNG<br />

• NICOTINE FORMULATIONS AND USE<br />

THEREOF<br />

• FORMULATIONS DE NICOTINE ET LEURS<br />

UTILISATIONS<br />

(73) McNeil AB, P.O.Box 941, 25109 Helsingborg,<br />

SE<br />

(72) EK, Bo, Ragnar, S-114 53 Stockholm, SE<br />

MIHRANYAN, Albert, 0021 Yerevan, AM<br />

ANDERSSON, Sven-Börje, S-112 87 Stockholm,<br />

SE<br />

BOSSON, Bengt, Ake, S-112 87 Stockholm,<br />

SE<br />

LINDBERG, Nils-Olof, S-216 15 Malmö, SE<br />

(74) Hedenström, John Allan, et al, Pfizer Health<br />

AB <strong>Patent</strong> Department P.O. Box 941, 251 09<br />

Helsingborg, SE<br />

A61K 9/50 → (51) B01J 13/04<br />

A61K 9/68 → (51) A61K 9/22<br />

A61K 9/70 → (51) A61K 9/22<br />

A61K 31/00 → (51) C12P 19/36<br />

(51) A61K 31/19 (11) 1 622 601 B1<br />

A61K 31/722 A61K 9/00<br />

(25) En (26) En<br />

(21) 04732650.9 (22) 13.05.2004<br />

(84) AT BE BG CH CY CZ DE DK EE ES FI FR GB<br />

GR HU IE IT LI LU MC NL PL PT RO SE SI SK<br />

TR<br />

(43) 08.02.2006<br />

(86) GB 2004/002057 13.05.2004<br />

(87) WO 2004/100941 2004/48 25.11.2004<br />

(30) 13.05.2003 GB 0310919<br />

(54) • PHARMAZEUTISCHE ZUBEREITUNGEN<br />

• PHARMACEUTICAL COMPOSITIONS<br />

• COMPOSITIONS PHARMACEUTIQUES<br />

(73) Archimedes Development Limited, Albert<br />

Einstein Centre, Nottingham Science &<br />

Technology Park, University Boulevard, Nottingham<br />

NG7 2TN, GB<br />

(72) LEANE, Michael, Hoylake, Merseyside CH47<br />

2AH, GB<br />

SMITH, Alan, Archimedes, Albert Einstein<br />

Centre, Nottingham NG7 2TN, GB<br />

ILLUM, Lisbeth, The Park, Nottingham NG7<br />

1BA, GB<br />

(74) Crowhurst, Charlotte Waveney, Potter Clarkson<br />

LLP Park View House 58 The Ropewalk,<br />

Nottingham NG1 5DD, GB<br />

A61K 31/4375 → (51) C<strong>07</strong>D 471/04<br />

A61K 31/4985 → (51) C<strong>07</strong>D 487/04<br />

A61K 31/4995 → (51) C<strong>07</strong>D 487/08<br />

A61K 31/50 → (51) C<strong>07</strong>D 401/12<br />

A61K 31/519 → (51) C<strong>07</strong>D 471/04<br />

(51) A61K 31/522 (11) 1 317 258 B1<br />

A61P 9/12<br />

(25) En (26) En<br />

(21) 01946722.4 (22) 28.06.2001<br />

(84) AT BE CH CY DE DK ES FI FR GB GR IE IT LI<br />

LU MC NL PT SE TR<br />

512<br />

<strong>Patent</strong>e<br />

<strong>Patent</strong>s<br />

Brevets (<strong>07</strong>/<strong>2009</strong>) 11.02.<strong>2009</strong><br />

(43) 11.06.2003<br />

(86) US 2001/020457 28.06.2001<br />

(87) WO 2002/000210 2002/01 03.01.2002<br />

(30) 28.06.2000 US 214825 P<br />

(54) • VERWENDUNG VON ALLOPURINOL ZUR<br />

BEHANDLUNG VON BLUTHOCHDRUCK<br />

• USE OF ALLOPURINOL FOR THE TREAT-<br />

MENT OF HYPERTENSION<br />

• UTILISATION DU ALLOPURINOL DANS LE<br />

TRAITEMENT DE L'HYPERTENSION<br />

(73) Merck & Co., Inc., 126 East Lincoln Avenue,<br />

Rahway, New Jersey <strong>07</strong>065-09<strong>07</strong>, US<br />

University of Washington, Technology<br />

Transfer Department, Suite 200, 11<strong>07</strong> NE<br />

45th Street, Box 354810, Seattle, WA 98105-<br />

4681, US<br />

(72) KIVLIGHN, Salah, Doylestown, PA 18901, US<br />

JOHNSON, Richard, J., Bellaire, TX 77410,<br />

US<br />

MAZZALI, Marilda, cAMPINAS-S.P. 13083-<br />

970, BZ<br />

(74) Germinario, Claudio, et al, Società Italiana<br />

Brevetti S.p.A. Piazza di Pietra, 38-39, 00186<br />

Roma, IT<br />

A61K 31/551 → (51) A61K 9/20<br />

A61K 31/551 → (51) C<strong>07</strong>D 471/04<br />

A61K 31/57 → (51) A61K 36/27<br />

A61K 31/58 → (51) A61K 36/27<br />

A61K 31/70 → (51) A61K 39/39<br />

A61K 31/7084 → (51) C12P 19/36<br />

A61K 31/722 → (51) A61K 31/19<br />

(51) A61K 35/76 (11) 1 309 334 B1<br />

A61P 35/00<br />

(25) En (26) En<br />

(21) 01953727.3 (22) 20.<strong>07</strong>.2001<br />

(84) AT BE CH CY DE DK ES FI FR GB GR IE IT LI<br />

LU MC NL PT SE TR<br />

(43) 14.05.2003<br />

(86) CA 2001/001055 20.<strong>07</strong>.2001<br />

(87) WO 2002/011742 2002/<strong>07</strong> 14.02.2002<br />

(30) 10.08.2000 US 636597<br />

(54) • KOMBINATIONSTHERAPIE MITTELS REO-<br />

VIRUS UND ANTI-ANTIREOVIRUS ANTI-<br />

KÖRPERN ZUR BEHANDLUNG VON RAS-<br />

VERMITTELTEN, PROLIFERATIVEN<br />

ERKRANKUNGEN<br />

• COMBINATION THERAPY USING REO-<br />

VIRUS AND ANTI-ANTIREOVIRUS ANTI-<br />

BODIES FOR THE TREATMENT OF RAS-<br />

MEDIATED PROLIFERATIVE DISORDERS<br />

• THERAPIE COMBINATOIRE UTILISANT<br />

DES REOVIRUS ET DES ANTICORPS ANTI-<br />

ANTIREOVIRUS POUR LE TRAITEMENT<br />

DES DESORDRES PROLIFERATIFS<br />

MEDIES PAR RAS<br />

(73) Oncolytics Biotech Inc., Suite 210 1167<br />

Kensington Crescent N. W., Calgary, AB T2N<br />

1X7, CA<br />

(72) COFFEY, Matthew, C., Calgary, Alberta T2N<br />

3L4, CA<br />

THOMPSON, Bradley, G., Calgary, Alberta<br />

T2N 0Z5, CA<br />

(74) Vossius & Partner, Siebertstraße 4, 81675<br />

München, DE<br />

(60) 08006359.7<br />

08006362.1 / 2 016 948<br />

A61K 36/185 → (51) A61K 36/8965<br />

A61K 36/23 → (51) A61K 36/8965

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!